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Highlights
• This EHA-ESMO Clinical Practice Guideline provides key 
recommendations on the management of multiple myeloma
• Authorship includes a multidisciplinary group of experts 
from different institutions and countries in Europe
• Key treatment recommendations are provided for both newly 
diagnosed myeloma patients and patients with relapsed/
refractory disease
• Recommendations for the treatment of plasma cell leukae-
mia, solitary plasmacytoma and smouldering myeloma are 
also provided
• Key recommendations for myeloma complications, including 
bone disease and renal impairment, are included
Incidence and epidemiology
Multiple myeloma (MM) is a plasma cell neoplasm that 
accounts for 1%-1.8% of all cancers and is the second most 
common haematological malignancy with an estimated inci-
dence in Europe of 4.5-6.0/100 000/y. Despite the significant 
improvement in patients’ survival over the past 20 years, only 
10%-15% of patients achieve or exceed expected survival com-
pared with the matched general population.1
Diagnosis and staging
In 2017, ESMO published clinical practice guidelines for the 
diagnosis, staging and definitions of progressive disease, relapse 
and refractoriness to therapy, which have not changed and are 
summarised in Supplementary Tables S1-S3, http://links.lww.
com/HS/A128.2
The recommendations for the tests that are required for the 
diagnosis, determination of prognosis and follow-up of MM are 
described in Table 1.
2
Dimopoulos et al EHA-ESMO Joint Guidelines for Multiple Myeloma
Response criteria to anti-myeloma therapy
One of the most significant improvements in the response 
criteria is the introduction of minimal residual disease (MRD) 
both in the bone marrow (BM) (using either next-generation 
sequencing or next-generation flow [NGF] cytometry) and out-
side the BM (using positron emission tomography-computed 
tomography [PET-CT]; imaging MRD).4 MRD negativity in 
the BM in patients who have achieved conventional complete 
response (CR) consistently correlates with prolonged pro-
gression-free survival (PFS) and overall survival (OS) in both 
newly diagnosed MM (NDMM) and relapsed/refractory MM 
(RRMM) patients.6,7
MRD negativity in the BM, defined as the absence of 
tumour plasma cells within 1 000 000 BM cells (<10–6) 
shows the best results for the prediction of both PFS and OS 
compared with higher cutoff values (ie, 10–5).6 Outside the 
BM, PET-CT is able to recognise hypermetabolic areas in 
approximately 15%-20% of patients with MRD negativity 
in the BM and is considered the best method for imaging 
MRD to date.8
MRD has been found to be a surrogate endpoint for PFS in 
patients receiving first-line treatment.9 Therefore, MRD may 
be used as an endpoint to accelerate drug development. The 
use of MRD to drive treatment decisions is under investiga-
tion, for example, whether maintenance/continuous therapy 
in MRD-negative patients can be stopped or whether treat-
ment needs to be changed in MRD-positive patients, espe-
cially in high-risk MM. The results of several phase III trials 
in the field will clarify the role of MRD in making decisions 
about therapy in MM.
Front-line therapy
Smouldering MM
Patients with standard- or intermediate-risk smouldering 
MM (SMM; see Supplementary Table S4, http://links.lww.com/
HS/A128) do not need immediate therapy. Myeloma treatment 
should be initiated according to the International Myeloma 
Working Group (IMWG) recommendations.10 Regarding 
Table 1
Recommendations on Examinations at Diagnosis, Response Assessment, During Follow-up and at Relapse of MM.
 Tool Diagnosis At Response At Follow-up At Relapse
Blood Blood count and blood smear Obligatory Obligatory Obligatory Obligatory
Serum electrophoresis and IF Obligatory Obligatory (IF for CR 
confirmation)
Obligatory (IF for CR 
patients)
Obligatory
Serum-free light chain Obligatory Obligatory to confirm sCR Obligatory Obligatory
Serum immunoglobulin levels Obligatory Obligatory Obligatory Obligatory
Renal and liver function tests Obligatory Obligatory Obligatory Obligatory
Calcium Obligatory Obligatory Obligatory Obligatory
Lactate dehydrogenase Obligatory Obligatory Obligatory Obligatory
Albumin, β2m Obligatory Not required Optional Obligatory
Flow cytometry Optional Not required Not required Optional
Urine Urine sample from 24 h urine collection to check for 
proteinuria and light-chain proteinuria
Obligatory Obligatory Obligatory Obligatory
Urine electrophoresis and IF electrophoresis Obligatory Obligatory (IF for CR 
confirmation)
Obligatory (IF for CR 
patients)
Obligatory
BM BM cytology and biopsy to confirm plasmacytosis 
and monoclonality
Obligatory Obligatory to confirm CR or 
for nonsecretory MM
Not required Optional (obligatory for 
nonsecretory disease)
NGF or NGS to detect clonal plasma cells Obligatory Obligatory to confirm MRD 
negativity in CR or sCR 
patients




Cytogenetics: karyotype and FISH for detection of 
del17p, t(4;14), t(14;16), ampl 1q/gain 1q, t(11;14)
Obligatory Not required Not required Obligatory for del17p, ampl 
1q/gain 1q and t(11;14)
Advanced techniques: GEP, NGS For clinical trials use only For clinical trials use only For clinical trials use 
only
For clinical trials use only
Imaging WBLD-CT Obligatory Not required When symptomatic 
(or CT of the symp-
tomatic area)
Obligatory
PET-CT Optional (it may be carried 
out instead of WBLD-CT if 
available)
Obligatory to confirm 
imaging MRD




Whole-body MRI Obligatory in WBLD-CT-nega-
tive cases and if PET-CT is not 
carried out
Not required When symptomatic Optional
Adapted with permission from Caers et al.3
aSustained MRD negativity is supported by IMWG guidelines,4 although it is not fully reimbursed in several countries. In a recent “Real-World” study, MRD assessments were carried out in 139 patients 
before starting lenalidomide maintenance after ASCT and/or at the achievement of CR, while additional assessments were subsequently carried out on an annual basis until sustained MRD negativity was 
confirmed. In total, 34.3% of patients who were MRD-positive after induction treatment achieved MRD-negative status during maintenance and ultimately had improved PFS. Sequential MRD assessments 
identified patients with progressively decreasing MRD levels who also had better PFS outcomes, compared with patients not showing a decreasing pattern of MRD.5
bRecommended based on panel consensus in order to confirm extramedullary MRD negativity in patients who are MRD-negative in the BM.
ASCT = autologous stem cell transplantation; β2m = beta-2 microglobulin; BM = bone marrow; CR = complete response; CT = computed tomography; FISH = fluorescence in situ hybridization;  GEP = gene 
expression profiling; IF = immunofixation; IMWG = International Myeloma Working Group; MM = multiple myeloma; MRD = minimal residual disease; MRI = magnetic resonance imaging; NGF = next-gener-
ation flow cytometry; NGS = next-generation sequencing; PET-CT = positron emission tomography-computed tomography; PFS = progression-free survival; sCR = stringent complete response; WBLD-CT = 
whole-body low-dose computed tomography.
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high-risk SMM, which is recently defined by the “20-20-20” 
rule (Supplementary Table S4, http://links.lww.com/HS/A128),11 
2 randomised, phase III studies have shown that lenalidomide 
plays a significant role in prolonging PFS. In the first study, 119 
patients with high-risk SMM (before the introduction of the new 
criteria for the definition of myeloma10) were randomly assigned 
either to receive treatment with the combination of lenalido-
mide plus dexamethasone (Rd) for 9 cycles followed by lenalid-
omide maintenance or to observation. At a median follow-up 
of 75 months, Rd improved both PFS (median PFS [mPFS] 
not reached versus 23 mo; P < 0.0001) and OS compared with 
observation (hazard ratio [HR] = 0.43; P = 0.024).12,13 However, 
this study was conducted several years ago and enrolled a num-
ber of patients who are considered as having MM according to 
the revised definition. In the second study,14 182 patients with 
intermediate- or high-risk SMM were randomly assigned either 
to receive lenalidomide monotherapy or to observation. At a 
median follow-up of 35 months, PFS was longer with lenalido-
mide (HR = 0.28; P = 0.002); this result was driven mainly by the 
high-risk SMM group.14 This study has not reported OS advan-
tage for the lenalidomide arm to date. Several phase II studies 
using daratumumab (Dara) monotherapy,15 isatuximab (Isa) 
monotherapy or other Rd-based regimens (with elotuzumab 
[EloRd], or with ixazomib) have shown encouraging results.
All the above data suggest that high-risk SMM patients 
should be encouraged to participate in randomised phase III 
trials to reveal the best treatment that offers OS advantage. To 
date, no treatment has been approved for SMM.
Newly diagnosed patients who are eligible for 
high-dose therapy and autologous transplantation
For fit NDMM patients, aged <70 years, without comor-
bidities, induction followed by high-dose therapy (HDT) with 
autologous stem cell transplantation (ASCT) and lenalidomide 
maintenance is the recommended treatment. Two recent phase 
III trials comparing the use or not of upfront ASCT, after triplet 
novel agent-based induction, showed that PFS was improved in 
the upfront ASCT arm.16-18 The first study was conducted by the 
French Myeloma Study Group and included 700 patients who 
were randomised to receive induction therapy with 3 cycles of 
bortezomib, lenalidomide and dexamethasone (VRd) and then 
consolidation therapy with either 5 additional cycles of VRd or 
high-dose melphalan (HDM) plus ASCT followed by 2 addi-
tional cycles of VRd. Patients in both groups received main-
tenance therapy with lenalidomide for 1 year. After a median 
follow-up of 44 months in the VRd-alone group and 43 months 
in the ASCT group, the mPFS was longer in the ASCT group 
(50 versus 36 mo; P < 0.001). This benefit was observed across 
all patient subgroups, including advanced Revised International 
Staging System (R-ISS) and high-risk cytogenetics. OS at 4 years 
was not different between the ASCT and the non-ASCT groups.17
The second study was conducted by the European Myeloma 
Network (EMN)—EMN02/HO95 trial—and included 1503 
patients who received an induction therapy with 3-4 cycles 
of bortezomib, cyclophosphamide and dexamethasone (VCD) 
followed by the first randomisation between bortezomib, mel-
phalan and prednisone (VMP) versus ASCT. A second rando-
misation to consolidation therapy (2 cycles of VRd) versus no 
consolidation was carried out after intensification therapy, to 
be followed by lenalidomide maintenance until progression or 
toxicity in both arms. With a median follow-up from the first 
randomisation of 60.3 months, the mPFS was improved with 
ASCT compared with VMP (56.7 versus 41.9 mo; P = 0.0001).18
Induction regimen
A 3-drug combination, including at least bortezomib and 
dexamethasone, has been the standard of care.2,19 Bortezomib, 
thalidomide, dexamethasone (VTD) induction showed bet-
ter response rates over VCD at the expense of a higher rate 
of peripheral neuropathy.20 VCD and bortezomib, doxorubi-
cin and dexamethasone (PAd) were equally effective in terms 
of response but VCD was less toxic.21 In single-arm studies, 
VRd produced high very good partial response (VGPR), CR 
and MRD negativity rates, as well as prolonged PFS.6,17,22-24 
However, there is no direct comparison between VTD with VRd 
induction before ASCT. There is only an integrated analysis of 
3 randomised trials, presented in abstract form, which showed 
that VRd produces higher VGPR and MRD negativity rates 
compared with VTD.25
The introduction of monoclonal antibodies (mAbs), and 
especially of Dara, in the front-line setting has changed the 
treatment landscape in MM. In the phase III CASSIOPEIA trial, 
4 cycles of induction with VTD (n = 542) were compared with 
4 cycles of VTD plus Dara (DaraVTD) (n = 543); patients then 
received a single ASCT followed by consolidation and mainte-
nance.26 PFS at 18 months showed the superiority of DaraVTD 
over VTD (93% versus 85%, P < 0.0001).27 The combination of 
Dara with VRd (DaraVRd) had better results. In the randomised 
phase II GRIFFIN study, 207 patients were randomly assigned 
to receive VRd ± Dara induction (4 cycles), ASCT, VRd ± Dara 
consolidation (2 cycles) and lenalidomide ± Dara maintenance 
(26 cycles). The 24-month PFS rates were 95.8% for DaraVRd 
and 89.8% for VRd.23
The substitution of bortezomib with the second-genera-
tion proteasome inhibitor (PI) carfilzomib (K) resulted in high 
sustained MRD negativity rate in carfilzomib, lenalidomide 
and dexamethasone (KRd) compared with VRd, especially in 
patients with advanced R-ISS.28 There is no direct comparison 
between VRd and KRd in NDMM patients who are eligible for 
ASCT; however, in the ENDURANCE trial (see Elderly patients’ 
section), which included <30% of patients who received an 
ASCT, there was no PFS difference between the 2 regimens.
Based on the above data, VRd is likely to offer the best 
risk-benefit profile to date among triplet combinations (II, B). 
The 4-drug combination DaraVTD is more efficacious than 
VTD (I, A) but comparisons are lacking versus DaraVRd or 
VRd (these regimens have not been approved by the European 
Medicines Agency [EMA]). The EMA approval of DaraVTD 
makes it a new standard of care for induction before ASCT. 
Novel studies that are ongoing compare DaraVRd versus VRd, 
DaraVCD versus VTD, or combinations with novel mAbs such 
as IsaVRd, IsaKRd or EloVRd will reveal the best induction reg-
imen in the future.
Conditioning regimen before ASCT
HDM (200 mg/m2) remains the standard conditioning regi-
men before ASCT for NDMM patients. The addition of busul-
fan to melphalan has not shown OS benefit over HDM.29,30 The 
addition of bortezomib to HDM did not improve the efficacy of 
the conditioning regimen and had higher toxicity.31
Consolidation therapy
The EMN02/HO95 study showed that at a median fol-
low-up of 42 months, consolidation therapy with 2 cycles of 
VRd improved mPFS compared with no consolidation (58.9 
versus 45.5 mo; P = 0.014).18 It must be noted that induction 
treatment in this study included 4 cycles of VCD and not VRd 
or DaraVTD.
The use of a second planned ASCT as consolidation has also 
been tested in clinical trials. In the EMN02/HO95 study, in 
centres with a policy of double ASCT, patients were assigned 
to receive VMP, single ASCT (ASCT-1) or 2 planned ASCTs 
(administered 2-3 mo apart; ASCT-2) to prospectively compare 
ASCT-1 with ASCT-2. Patients who received ASCT-2 had a 
prolonged PFS compared with those who received ASCT-1: the 
3-year PFS probability was 53.5% for ASCT-2 versus 44.9% for 
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ASCT-1 group (P = 0.036), which represented a 26% reduced 
risk of progression or death in the ASCT-2 group. Importantly, 
ASCT-2 significantly improved the outcome of patients with 
high-risk cytogenetics (mPFS: 46 and 26.7 mo for ASCT-2 and 
ASCT-1, respectively; HR = 0.59; P = 0.062).16 In the same study, 
OS from the first randomisation was significantly prolonged 
with ASCT-2 compared with ASCT-1 (3-y rate: 89% versus 
82%; HR = 0.52; P = 0.011); this benefit was also reported in 
patients with R-ISS II + III (HR = 0.48; P = 0.013) and with high-
risk cytogenetics (HR = 0.52; P = 0.042).16
The phase III StaMINA study randomised 758 patients who 
received induction therapy for up to 12 cycles, followed by 1 
ASCT versus tandem ASCT versus ASCT-1 followed by 4 subse-
quent cycles of VRd; all treatment groups received lenalidomide 
maintenance until disease progression.32 The 6-year PFS in high-
risk patients was 43.6% and 26% for tandem ASCT and ASCT-1, 
respectively (P = 0.03).33
Finally, a study which compared tandem ASCTs with ASCT-1 
followed by allogeneic SCT (allo-SCT) has recently reported 
the 10-year median follow-up results. In both standard-risk 
(n = 625) and high-risk patients (n = 85), there was no PFS or OS 
difference.34
Maintenance therapy
Treatment with lenalidomide maintenance after ASCT 
offers PFS and OS benefits over placebo as reported in 2 
large randomised trials.35,36 A meta-analysis including 
more than 1200 patients, with a median follow-up of 79.5 
months, showed that lenalidomide maintenance offers more 
than 2 years of PFS benefit (52.8 versus 23.5 mo) and 2.5 
years of OS benefit over placebo. In this study, there was 
no benefit in patients with ISS-III disease or high-risk cyto-
genetics.37 However, the Medical Research Council (MRC) 
myeloma-XI trial, in which 1137 patients were assigned to 
lenalidomide maintenance and 834 patients to observation, 
showed that, in high-risk patients, the 3-year OS was 75% 
in the lenalidomide group compared with 64% in the obser-
vation group, and in ultra-high-risk patients it was 63% ver-
sus 43.5%, respectively.38 These results should be taken with 
caution as the study was not powered to show differences 
in the 2 sub-populations and all patients who entered the 
maintenance phase were immunomodulatory drug (IMiD)-
exposed and -sensitive. Furthermore the definition of high-
risk patients was different in the meta-analysis and in the 
MRC-XI trial; in the meta-analysis, high-risk cytogenet-
ics included only t(4;14) and del17p patients while in the 
MRC-XI trial patients were classified into 3 cytogenetic risk 
groups: standard risk (no adverse cytogenetic abnormalities), 
high risk (1 adverse cytogenetic abnormality), or ultra-high 
risk (2 or more adverse cytogenetic abnormalities) [adverse 
cytogenetic abnormalities were defined as gain(1q), t(4;14), 
t(14;16), t(14;20), or del(17p)].37,38 The EMA has approved 
lenalidomide for maintenance therapy post-ASCT for all 
MM patients until progression.
Bortezomib maintenance showed PFS benefit compared with 
thalidomide maintenance in a randomised study, but the induc-
tion treatment was not the same between the 2 treatment groups 
(PAd versus vincristine, doxorubicin and dexamethasone [VAD], 
respectively).39 A recent double-blind, placebo-controlled, phase 
III trial (TOURMALINE-MM3) compared the oral PI ixazomib 
with placebo in 656 patients who received induction therapy 
plus HDM + ASCT. There was a 28% reduction in the risk of 
progression or death with ixazomib (mPFS: 26.5 versus 21.3 
mo, respectively; P = 0.0023). In the high-risk population, ixazo-
mib also offered similar PFS advantage over placebo (HR = 0.62, 
95% confidence interval = 0.38-1.02).40 Bortezomib and ixazo-
mib have not yet been approved by the EMA for maintenance 
after ASCT.
Elderly patients or patients with NDMM who 
are not eligible to receive HDT and autologous 
transplantation
Before 2019, VMP and Rd were the standards of care 
for NDMM patients who were not eligible for an ASCT in 
Europe.41,42 A phase III trial comparing VRd with Rd in 525 
NDMM patients (43% were younger than 65 y old) was 
recently updated and showed the superiority of VRd regard-
ing PFS (mPFS: 41 versus 29 mo; P = 0.003) and OS (median 
OS [mOS] not reached versus 69 mo; P = 0.0114).43 Based on 
these results, the EMA approved VRd in April 2019 for use in 
NDMM patients who are not eligible for ASCT. The substitu-
tion of bortezomib with K in the Rd combination seems not to 
offer better results. The ENDURANCE trial, which compared 
KRd versus VRd in NDMM patients without an immediate 
intent for ASCT, failed to show superiority of KRd regarding 
PFS in the study population (n = 1087), which included a low 
number of patients with high-risk cytogenetics.44
The addition of Dara to VMP and Rd has created 2 new 
standards of care. DaraVMP and DaraRd were approved by 
the EMA in October 2019, based on the results of 2 large phase 
III studies. In the ALCYONE study, 706 patients with NDMM 
who were ineligible for ASCT were randomised to receive 9 
cycles of VMP either alone or with Dara (DaraVMP); then Dara 
was given until disease progression.45 At a median follow-up 
of 40 months, the mPFS was 36.4 versus 19.3 months for the 
DaraVMP and VMP arms, respectively, while the 36-month 
rate of OS was 78% and 68% for the 2 groups (HR = 0.60; 
P = 0.0003).46 In the MAIA study, 737 NDMM patients who 
were ineligible for ASCT were randomised to receive either 
DaraRd or Rd until disease progression. At a median follow-up 
of 28 months, the estimated PFS at 30 months was 70.6% in 
the DaraRd group and 55.6% in the Rd group (HR = 0.56; 
P < 0.001).47
Other approved regimens in this setting include bendamus-
tine plus prednisone48 and melphalan, prednisone and lenalid-
omide (MPR),49 but they are not routinely used and cannot be 
considered as standards of care.
It is important to realise that one-third of patients are older 
than 75 years at diagnosis and at least 30% are frail. Please refer 
to Management of frail elderly patients in the Supplementary 
Material, http://links.lww.com/HS/A128, for consensus panel 
recommendations for the management of these patients.
Although maintenance is not standard for patients who are 
not eligible for ASCT (almost all approved regimens are used 
continuously until progression or unacceptable toxicity), ixazo-
mib maintenance was tested in a phase III study which included 
706 patients who received 6-12 months of standard induction 
before being randomised to receive either ixazomib or placebo. 
Ixazomib maintenance offered a PFS benefit over placebo (17.4 
versus 9.4 months, HR = 0.65, P = 0.00003).50 Figure 1 depicts 
the first-line options for the treatment of NDMM patients.
Recommendations
• “Watch-and-wait” remains the recommended approach for 
SMM (II, B). High-risk patients are encouraged to partici-
pate in randomised phase III studies that are powered for OS 
advantage of the experimental treatment modality.
• For patients <70 years without comorbidities, induction ther-
apy followed by HDM and ASCT is the recommended treat-
ment (I, A).
• Regarding induction therapy pre-ASCT, VRd is likely to offer 
the best risk-benefit profile to date among triplets based on 
bortezomib (II, B); however, VRd lacks direct comparisons 
with VTD or DaraVTD and is not licensed by the EMA. The 
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4-drug combination DaraVTD is more efficacious than VTD 
(I, A) and is the new standard of care. If this is not available, 
VTD (I, A) or VCD (II, B) may be used. DaraVRd and Isa-
VRd are under clinical investigation and may be standards 
of care in the near future. Induction with 4-6 cycles is the 
recommended approach.
• HDM (200 mg/m2) is the standard conditioning regimen 
before ASCT (I, A).
• Consolidation therapy post-ASCT has not been established to 
date as standard therapy; 2 cycles of VRd consolidation has 
to be considered in patients who receive VCD induction (II, 
B), while a tandem ASCT is recommended for patients with 
genetically defined high-risk disease (II, B) or in all patients 
who received VCD induction (II, B). Allo-SCT following 
ASCT does not offer OS benefit even in high-risk disease com-
pared with tandem ASCT.
• Maintenance with lenalidomide is considered the standard 
of care for all MM patients post-ASCT (I, A); bortezomib 
may be considered for patients with high-risk disease (II, B). 
Ixazomib maintenance offers PFS benefit over placebo (I, A), 
but has not been approved by the EMA or the US Food and 
Drug Administration (FDA).
• For patients who are not eligible for ASCT, there are 3 new 
standards of care: VRd, DaraVMP and DaraRd (I, A). When 
DaraRd and DaraVMP are not available, VRd is the preferred 
option in fit patients; Rd and VMP may be considered for 
patients who cannot receive the previous regimens (I, A).
Treatment of relapsed/refractory patients
Patients who have received 1 prior line of therapy
Salvage ASCT may be an option for patients who have 
received front-line induction with bortezomib-based triplet 
combination followed by an ASCT. Two prospective studies of 
salvage ASCT have been published so far. The first included a 
bortezomib-based re-induction and a randomisation between 
Figure 1. Recommendations for MM front-line therapy. ASCT = autologous stem cell transplantation; DaraRd = daratumumab/lenalidomide/dexamethasone; DaraVMP = 
daratumumab/bortezomib/melphalan/prednisone; DaraVTD = daratumumab/bortezomib/thalidomide/dexamethasone; MM = multiple myeloma;  Rd = lenalidomide/dexamethasone; VCD = 
bortezomib/cyclophosphamide/dexamethasone; VMP = bortezomib/melphalan/prednisone; VRd = bortezomib/lenalidomide/dexamethasone; VTD = bortezomib/thalidomide/dexamethasone.
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salvage ASCT or cyclophosphamide, which is suboptimal 
for relapsed patients. Salvage ASCT significantly extended 
mPFS (19 versus 11 mo; P < 0.001) and OS (67 versus 52 mo; 
P = 0.0169).51 The second included patients with first to third 
relapse who were randomised to a transplant arm (n = 139) 
consisting of 3 Rd re-induction cycles, ASCT and lenalidomide 
maintenance (10 mg/d) or to a control arm (n = 138) of con-
tinuous Rd. Although there was no difference regarding PFS 
and OS between the 2 arms, almost 30% of the patients in 
the transplant arm did not receive the assigned ASCT mainly 
due to early disease progression. Multivariate landmark 
analyses from the time of ASCT showed superior PFS and 
OS (P = 0.0087 and P = 0.0057, respectively) in patients who 
received ASCT.52 The American and European Associations for 
Bone and Marrow Transplantation have reported that HDT 
and ASCT should be considered appropriate treatment of any 
patient relapsing after primary therapy that includes an ASCT 
with initial remission duration of >18 months.53 However, this 
recommendation was made before the broad use of lenalido-
mide as maintenance therapy post-ASCT. Although there is no 
evidence for the role of salvage ASCT in patients who received 
lenalidomide maintenance, the panel suggests that second-line 
ASCT is a logical approach for patients who relapse after pri-
mary therapy that includes an ASCT followed by lenalidomide 
maintenance and had an initial remission duration of ≥36 
months. The use of re-induction is a matter of debate as there 
is no prospective study on this issue. Retrospective studies sug-
gest that the use of re-induction does not offer survival benefit 
in salvage ASCT.54
In patients in whom a salvage ASCT is not considered, the 
second-line therapy should include an Rd-based regimen, 
that is, KRd, DaraRd, ixazomib/lenalidomide/dexamethasone 
(IRd) or EloRd for patients who received a bortezomib-based 
therapy upfront without lenalidomide or Dara (ie, VCD, VTD, 
VMP); all these combinations were found to be superior to 
Rd, in terms of PFS, in pivotal phase III studies.55-58 Based on 
both HR and absolute values of mPFS, DaraRd provides the 
longest PFS for patients with RRMM who have received 1-3 
prior lines of therapy and have a standard-risk cytogenetic 
profile. KRd and EloRd have also shown OS benefit over Rd: 
mOS 48.3 versus 40.4 months for KRd versus Rd (HR = 0.79; 
P = 0.0045),59 and 48.3 versus 39.6 months for EloRd versus 
Rd,60 respectively. DaraRd is likely to have OS benefit over 
Rd, but mature data have not been presented, while IRd has 
no OS benefit over Rd. For relapsed patients with high-risk 
cytogenetics, although different cutoff values are used for the 
definition of del17p positivity, all above triplets have shown 
better results compared with Rd; however, the combination of 
a PI with Rd, that is, KRd or IRd, along with DaraRd seem to 
offer the best benefit to date.
Elderly patients who received Rd upfront without Dara61 or 
patients who received lenalidomide maintenance after ASCT 
and are progressing (lenalidomide-refractory patients), accord-
ing to previous guidelines, could receive either K plus dexa-
methasone (Kd) or Dara and bortezomib plus dexamethasone 
(DaraVd) (patients treated with Kd or DaraVd had significantly 
improved PFS compared with Vd).62,63 Three phase III studies 
suggest that the combination of pomalidomide with bortezo-
mib and dexamethasone (PomVd) and the combinations of 
Dara or Isa with K and dexamethasone (DaraKd or IsaKd) 
are new options for this setting.62-64 In the first study, PomVd 
(n = 278) was compared with Vd (n = 270) in RRMM patients 
who had received 1-3 prior lines of therapy that included lena-
lidomide. More than 70% of the patients were refractory to 
lenalidomide. After a median follow-up of 16 months, PomVd 
improved mPFS in the study population (11.2 versus 7.1 mo; 
HR = 0.61; P < 0.0001) as well as in patients refractory to lena-
lidomide (9.5 versus 5.6 mo; P = 0.0008) and in patients refrac-
tory to lenalidomide who received only 1 prior line of treatment 
(17.8 versus 9.5 mo; P = 0.03).64 PomVd was approved by the 
EMA in May 2019.
In the second study (CANDOR), DaraKd was compared 
with Kd in RRMM patients who had received 1 prior line of 
therapy. This study showed that the mPFS was not reached for 
the DaraKd group and it was 15.8 months for the Kd group 
(HR = 0.63; P = 0.0014). DaraKd resulted in a better PFS benefit 
both among lenalidomide-exposed (HR = 0.52) and lenalido-
mide-refractory patients (HR = 0.45).65
Finally, in the third study, which was reported at the EHA 
2020 meeting, only 302 patients with RRMM and 1-3 prior 
lines of therapy were randomised to receive either IsaKd 
(n = 179) or Kd (n = 123). At a median follow-up of 20.7 months, 
mPFS was not reached for IsaKd whereas it was 19.1 months 
for Kd (HR = 0.53; P = 0.0007).66
Thus, PomVd, DaraKd and IsaKd are recommended thera-
pies for patients who were previously exposed or are refractory 
to lenalidomide, while DaraKd or IsaKd can also be given in 
patients who are refractory to bortezomib.
The approval of Dara-based regimens (DaraVTD, DaraVMP 
and DaraRd) and of VRd, as first-line therapy for myeloma 
patients, makes the treatment of second and subsequent lines of 
therapy very challenging. Although there is some evidence that 
Dara retreatment can be efficacious in some patients,67,68 there 
are no data for Dara retreatment at second line.
Venetoclax is a selective B-cell lymphoma 2 inhibitor that pro-
motes MM cell apoptosis. The phase III BELLINI trial evaluated 
the combination of venetoclax with Vd (VenVd) compared with 
Vd among RRMM patients, who had received 1-3 prior lines 
of therapy and were PI-sensitive. A significant PFS benefit was 
reported with VenVd among patients with t(11;14) (HR = 0.10; 
P = 0.003) and those with high BCL2 expression (HR = 0.26; 
P < 0.001) but no OS difference was shown in this population. 
On the contrary, Vd was superior to VenVd in terms of OS 
among patients without t(11;14) and low BCL2 (HR = 3.13; 
P = 0.019).69 Therefore, VenVd is an option only for patients 
with t(11;14) or high BCL2 levels who have failed lenalidomide 
and are sensitive to PI. VenVd is awaiting EMA approval.
Selinexor is an oral, selective inhibitor of exportin 1 pro-
tein-mediated nuclear export, leading to the reactivation of 
tumour-suppressor proteins. Selinexor in combination with 
Vd (SVd) was compared with Vd in a phase III study with 402 
patients with RRMM who received 1-3 prior lines of therapy. 
SVd significantly prolonged mPFS compared with Vd (13.9 ver-
sus 9.4 mo, HR = 0.70, P = 0.0066), suggesting that SVd might 
be another option in patients who were treated with lenalido-
mide-based regimens upfront.70 SVd is awaiting EMA approval.
In Figure 2, the possible options for second-line therapy, tak-
ing into consideration the previous line and the refractoriness to 
specific agents, are described. For Dara-previously exposed or 
-refractory patients, the recommendations are based on panel 
opinion as there is no evidence for the efficacy of the approved 
second-line regimens in these patients to date.
Patients who have received 2 or more prior lines of 
therapy
Treatment of RRMM patients who received 2 or more prior 
lines of therapy is becoming challenging.71 A recent study 
revealed that patients who are refractory to 2 PIs, 2 IMiDs and 
a CD38 mAb have an mOS of 5.6 months only.72 For patients 
who have been exposed or are refractory to both bortezomib 
and lenalidomide, who have not received an mAb, DaraKd or 
IsaKd are suitable options. The combinations of Elo or Isa with 
pomalidomide and dexamethasone (EloPd and IsaPd, respec-
tively) are suitable options for patients who have failed ≥2 lines 
of previous therapies, including lenalidomide and a PI, based on 
the results of 2 studies. The first was a phase II study, in which 
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patients were randomly assigned to receive either EloPd (n = 60) 
or Pd (n = 57). After a follow-up period of 9 months, the mPFS 
was 10.3 months in the EloPd group and 4.7 in the Pd group 
(HR = 0.54; P = 0.008).73 The second was a phase III study, in 
which patients were randomised to receive either IsaPd (n = 154) 
or Pd (n = 153). At a median follow-up of 11.6 months, mPFS 
was 11.5 months in the IsaPd group versus 6.5 months in the Pd 
group (HR = 0.596; P = 0.001).74 EloPd and IsaPd were recently 
approved by the EMA in this setting.
The combination of Dara with pomalidomide and dexameth-
asone (DaraPd) has been approved by the FDA for patients who 
have failed ≥2 lines of previous therapies, including lenalido-
mide and a PI. This was based on a phase II nonrandomised 
study where DaraPd was given in 103 patients with RRMM. 
At a median follow-up of 13 months, the mPFS was 8.8 months 
and the mOS was 17.5 months.75 DaraPd has not yet been 
approved by the EMA, as the results of the phase III APOLLO 
study (DaraPd versus Pd) are pending.
Patients with t(11;14), who are refractory to lenalidomide 
and are PI-sensitive may be treated with VenVd, when this regi-
men is licensed, as previously discussed.
For triple-class refractory patients, selinexor-dexamethasone 
(Sd) or belantamab mafodotin monotherapy may be suitable 
options. In a phase II study with 122 RRMM patients (median 
number of 7 prior lines of therapy), oral selinexor was given 
with dexamethasone twice weekly. An mPFS of 3.7 months 
and an mOS of 8.6 months were reported. Fatigue, nausea and 
decreased appetite were common and were typically grade 1 or 
2 events; grade 3 events were noted in up to 25% of patients 
and no grade 4 events were reported.76
Belantamab mafodotin is an antibody-drug conjugate tar-
geting B-cell maturation antigen (BCMA). In a phase II study, 
196 patients with triple-class refractory MM received 2 differ-
ent doses of belantamab mafodotin (2.5 and 3.4 mg/kg). The 
mPFS was 2.9 and 4.9 months for the 2 doses, respectively. 
The most common grade 3-4 adverse events included keratop-
athy (27% and 21% of patients for the 2 doses, respectively), 
thrombocytopaenia and anaemia.77 Melflufen may also be 
beneficial in Dara and pomalidomide-refractory patients but 
the results of the phase III trial have not yet been reported.78
Figure  3 summarises the recommendations for RRMM 
patients who receive third or subsequent lines of therapy.
Immunotherapy strategies targeting BCMA or other anti-
gens on the surface of myeloma cells, including bispecific T-cell 
engagers (BiTEs) and chimeric antigen receptor T (CAR-T) cells, 
are under clinical investigation in RRMM patients. Results for 
the first published study with a CAR-T cell product in myeloma 
patients showed that infusion of bb2121 in 33 consecutive 
patients with multirefractory disease resulted in an objective 
response rate of 85%, including 15 patients (45%) with CR; 
all were MRD-negative. The mPFS was 11.8 months. CAR-T 
cell expansion was associated with better responses and CAR-T 
cells persisted up to 1 year after the infusion. A total of 25 
patients (76%) had cytokine release syndrome, while neurolog-
ical toxic effects occurred in 14 patients (42%).79 Several stud-
ies using other CAR-T cell products or T-cell engagers (TCEs) 
were reported in the American Society of Clinical Oncology 
(ASCO) and EHA 2020 meetings and had similar results, sug-
gesting that these immunotherapy techniques may increase sur-
vival of myeloma patients (see Supplementary Material, http://
links.lww.com/HS/A128, section on novel immunotherapies for 
myeloma).
Recommendations
Patients who receive second-line therapy
• Second-line ASCT is an option for patients who received 
primary therapy that included an ASCT followed by 
Figure 3. Recommendations for MM patients who received a  third or subsequent line of therapy. aOnly phase IB data are published for 
DaraPd. Publication of phase III data are expected in 2021. bFor patients with t(11;14) or high BCL2 levels. Dara = daratumumab; Elo = elotuzumab; IMiD = 
immunomodulatory drug; Isa = isatuximab; Kd = carfilzomib/dexamethasone; mAb = monoclonal antibody; MM = multiple myeloma; PCd = pomalidomide/cyclophosphamide/
dexamethasone; Pd = pomalidomide/dexamethasone; PI = proteasome inhibitor; S = selinexor; Sd = selinexor/dexamethasone; Vd = bortezomib/dexamethasone; Ven = venetoclax.
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lenalidomide maintenance and had an initial remission 
duration of ≥36 months (panel consensus).
• Patients who had received a bortezomib-based therapy 
upfront without lenalidomide or Dara should receive an 
Rd-based regimen, that is, KRd, DaraRd, IRd or EloRd (I, 
A). DaraRd provides the best PFS for these patients, while 
only KRd and EloRd showed an OS benefit over Rd to date.
• Patients who are refractory to lenalidomide upfront could 
receive either PomVD, DaraKd, IsaKd or DaraVd (I, A). 
PomVd is the approved indication with best results, in terms 
of PFS, as second-line therapy in lenalidomide-refractory 
patients. DaraKd has given the best reported PFS to date in 
lenalidomide-refractory patients, but DaraKd is awaiting EMA 
approval. Similarly, IsaKd and SVd, which are also suitable for 
this setting (I, A), have not yet been approved by the EMA.
• VenVd is a suitable option for patients with t(11;14) who 
have failed lenalidomide and are sensitive to PIs (I, A), if 
available.
Patients at third and subsequent lines of treatment
• For patients who have been exposed or are refractory to 
both bortezomib and lenalidomide, DaraKd (I, A), IsaPd (I, 
A), IsaKd (I, A) and EloPd (II, B) are recommended.
• Patients with t(11;14), who are refractory to lenalidomide and 
are PI-sensitive may be treated with VenVd (I, A), if available.
• For triple-class refractory patients, Sd or belantamab 
mafodotin monotherapy is recommended (II, B), if avail-
able. Results of phase III studies of melflufen, TCEs and 
CAR-Ts in triple-class refractory patients are awaited.
Management of plasma cell leukaemia
Primary plasma cell leukaemia (PPCL) is a rare and aggressive 
variant of MM, operationally defined by the presence of 20% 
and/or an absolute number >2 × 109/L of clonal plasma cells in 
the peripheral blood without a previous history of MM.80 The 
cutoff value of circulating plasma cells for the definition of PCL 
may be reduced to 5% in the near future, as the survival of these 
patients is similar to those with 20% of circulating plasma cells.76 
PPCL should be distinguished from secondary PCL, which gener-
ally constitutes the leukaemic evolution of a preexisting, end-stage 
RRMM, and from extramedullary myeloma. Diagnostic work-up 
and staging procedures in PPCL are similar to those applied in 
MM. However, they have to be implemented by peripheral blood 
analysis for measuring circulating PC count and PET-CT for 
detecting possible extramedullary lesions.81
The outcome of patients with PCL remains poor and the mOS 
is around 1 year.80,81 There are no precise guidelines for the treat-
ment of PPCL due to the lack of phase III trials in this setting. 
Only 2 prospective phase II studies have been published so far 
for PPCL.82,83 Overall, treatment should be immediate and possi-
bly oriented toward bortezomib and/or lenalidomide-based mul-
tiphase approaches in combination with chemotherapy agents, 
with short treatment-free intervals. It should ideally include 
induction, double ASCT, consolidation and maintenance (II, B). 
KRd may be another option for these patients84 but more data are 
needed before a recommendation can be made for PCL patients.
Allo-SCT should be considered in selected cases (III, C). In a 
recent study, 71 patients (median age 56 y) with PPCL underwent 
an allo-SCT and the 4-year outcomes were: nonrelapse mortality 
12%, PFS 19% and OS 31%.85 Thus, in patients younger than 
50 years of age with a suitable donor, a myeloablative allo-SCT 
can be considered. Otherwise, a tandem transplant with an ASCT 
followed by a reduced-intensity conditioning allo-SCT if a related 
or an unrelated donor is available can be considered (IV, C).
Patients not eligible for transplant procedures should prefer-
ably receive continuous treatment (III, C). In relapsed/refractory 
PPCL, a switch to drugs not used at diagnosis should be consid-
ered, favouring combinations of lenalidomide or pomalidomide 
plus dexamethasone with K or mAbs (Dara or Elo) (expert con-
sensus). See Supplementary Table S6, http://links.lww.com/HS/
A128, for summary recommendations.
Management of solitary plasmacytoma
Solitary plasmacytoma is an infrequent form of plasma cell 
neoplasm that presents as a single mass of monoclonal plasma 
cells, with either extramedullary or intraosseous location.3,86 
Clonal PCs are typically absent in the BM aspirate by conven-
tional morphology or immunohistochemistry and there are no 
other MM features (hypercalcaemia, anaemia or renal disease 
attributable to MM).10 In some patients, a BM aspiration can 
detect a low monoclonal plasma cell infiltration, which indi-
cates a high risk of early progression to an overt myeloma 
disease.3,86 Furthermore, in a study following the use of high 
sensitivity flow cytometry, half of the patients showed occult 
BM infiltration and half of these cases progressed at 2 years.87 
Thus, detection of clonal PC using sensitive techniques in the 
BM is suggested (II, B) and systemic treatment of myeloma 
should be considered in these patients (III, B). Before treatment 
initiation, whole-body magnetic resonance imaging (MRI) and 
PET-CT should be carried out to exclude the presence of multi-
ple plasmacytomas, commending systemic treatment instead of 
radiotherapy (RT) (I, A).8,88 Local high-dose RT is the preferred 
treatment of choice (II, A), but about two-thirds of patients 
develop MM at 10 years’ follow-up.89 With current staging tech-
niques, that is, NGF and PET-CT, the incidence of solitary plas-
macytoma is expected to decrease and the cure rate to increase. 
See Supplementary Table S6, http://links.lww.com/HS/A128, for 
summary recommendations.
Supportive care
Recommendations for the management of myeloma compli-
cations, that is, bone disease, anaemia, BM failure, infections, 
vaccination strategies and renal impairment, are described in the 
Supplementary Material, http://links.lww.com/HS/A128, in the 
section on Supportive Care.
Follow-up and long-term implications
Table 1 includes all tests that have to be carried out during 
follow-up of myeloma patients. Full blood count, serum and 
urine electrophoresis and serum-free light chain (sFLC) deter-
mination, creatinine and calcium tests should be carried out 
monthly or at least every 3 months. sFLC should be used to 
detect light chain escape. In cases of relapsed patients with no 
positivity for del17p or add1q at diagnosis, fluorescence in situ 
hybridization analysis for del17p and add1q should be carried 
out to reveal high-risk relapse. In case of bone pain, whole-
body low-dose CT (WBLD-CT), MRI or PET-CT should be 
carried out to detect new bone lesions.3
MM has for a long time been considered as an incurable dis-
ease. Recent trials incorporating novel agents and ASCT report 
a statistical cure fraction of more than 15%.1,24 The addition of 
quadruplet combinations including mAbs as part of front-line 
therapies and novel immunotherapy strategies seems to further 
increase this apparent cure rate.
Personalised medicine
The presence of t(11;14) in RRMM patients should be inves-
tigated to decide for venetoclax-based regimens, when available 
in Europe. Otherwise, no prognostic factor or staging system, 
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including R-ISS or gene-expression profiling, is used routinely 
to define a risk-adapted strategy. In myeloma, more research 
is needed to identify molecular markers which could lead to 
advances in personalised medicine.
Methodology
These Clinical Practice Guidelines were developed in accor-
dance with the ESMO standard operating procedures for 
Clinical Practice Guidelines development (www.esmo.org/
Guidelines/ESMO-Guidelines-Methodology). An interdisciplin-
ary panel of clinical experts on MM, members of ESMO, EHA, 
and EMN selected the relevant literature. Levels of evidence 
and grades of recommendations were assigned according to the 
adapted Infectious Diseases Society of America-United States 
Public Health Service Grading System (Supplementary Table 
S7, http://links.lww.com/HS/A128).90 Statements without grad-
ing were considered justified standard clinical practice by the 
experts.
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